Academic Journal
View in EDS

Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)

Bibliographic Details
Title: Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)
Authors: Zoltán Kiss, István Wittmann, Lőrinc Polivka, György Surján, Orsolya Surján, Zsófia Barcza, Gergő Attila Molnár, Dávid Nagy, Veronika Müller, Krisztina Bogos, Péter Nagy, István Kenessey, András Wéber, Mihály Pálosi, János Szlávik, Zsuzsa Schaff, Zoltán Szekanecz, Cecília Müller, Miklós Kásler, Zoltán Vokó
Source: Frontiers in Immunology, Vol 13 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Immunologic diseases. Allergy
Subject Terms: SARS-CoV2 infection, booster vaccine, 4th vaccine, omicron variant (SARS-CoV-2), delta variant (B.1.617.2), vaccine effectiveness, Immunologic diseases. Allergy, RC581-607
More Details: BackgroundIn Hungary, the pandemic waves in late 2021 and early 2022 were dominated by the Delta and Omicron SARS-CoV-2 variants, respectively. Booster vaccines were offered with one or two doses for the vulnerable population during these periods.Methods and FindingsThe nationwide HUN-VE 2 study examined the effectiveness of primary immunization, single booster, and double booster vaccination in the prevention of Covid-19 related mortality during the Delta and Omicron waves, compared to an unvaccinated control population without prior SARS-CoV-2 infection during the same study periods. The risk of Covid-19 related death was 55% lower during the Omicron vs. Delta wave in the whole study population (n=9,569,648 and n=9,581,927, respectively; rate ratio [RR]: 0.45, 95% confidence interval [CI]: 0.44–0.48). During the Delta wave, the risk of Covid-19 related death was 74% lower in the primary immunized population (RR: 0.26; 95% CI: 0.25–0.28) and 96% lower in the booster immunized population (RR: 0.04; 95% CI: 0.04–0.05), vs. the unvaccinated control group. During the Omicron wave, the risk of Covid-19 related death was 40% lower in the primary immunized population (RR: 0.60; 95% CI: 0.55–0.65) and 82% lower in the booster immunized population (RR: 0.18; 95% CI: 0.16–0.2) vs. the unvaccinated control group. The double booster immunized population had a 93% lower risk of Covid-19 related death compared to those with only one booster dose (RR: 0.07; 95% CI. 0.01–0.46). The benefit of the second booster was slightly more pronounced in older age groups.ConclusionsThe HUN-VE 2 study demonstrated the significantly lower risk of Covid-19 related mortality associated with the Omicron vs. Delta variant and confirmed the benefit of single and double booster vaccination against Covid-19 related death. Furthermore, the results showed the additional benefit of a second booster dose in terms of SARS-CoV-2 infection and Covid-19 related mortality.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-3224
Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2022.905585/full; https://doaj.org/toc/1664-3224
DOI: 10.3389/fimmu.2022.905585
Access URL: https://doaj.org/article/70e11602c34c455887a03c15bc33e950
Accession Number: edsdoj.70e11602c34c455887a03c15bc33e950
Database: Directory of Open Access Journals
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=16643224&ISBN=&volume=13&issue=&date=20220601&spage=&pages=&title=Frontiers in Immunology&atitle=Nationwide%20Effectiveness%20of%20First%20and%20Second%20SARS-CoV2%20Booster%20Vaccines%20During%20the%20Delta%20and%20Omicron%20Pandemic%20Waves%20in%20Hungary%20%28HUN-VE%202%20Study%29&aulast=Zolt%C3%A1n%20Kiss&id=DOI:10.3389/fimmu.2022.905585
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/70e11602c34c455887a03c15bc33e950
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.70e11602c34c455887a03c15bc33e950
RelevancyScore: 942
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 942.390075683594
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Zoltán+Kiss%22">Zoltán Kiss</searchLink><br /><searchLink fieldCode="AR" term="%22István+Wittmann%22">István Wittmann</searchLink><br /><searchLink fieldCode="AR" term="%22Lőrinc+Polivka%22">Lőrinc Polivka</searchLink><br /><searchLink fieldCode="AR" term="%22György+Surján%22">György Surján</searchLink><br /><searchLink fieldCode="AR" term="%22Orsolya+Surján%22">Orsolya Surján</searchLink><br /><searchLink fieldCode="AR" term="%22Zsófia+Barcza%22">Zsófia Barcza</searchLink><br /><searchLink fieldCode="AR" term="%22Gergő+Attila+Molnár%22">Gergő Attila Molnár</searchLink><br /><searchLink fieldCode="AR" term="%22Dávid+Nagy%22">Dávid Nagy</searchLink><br /><searchLink fieldCode="AR" term="%22Veronika+Müller%22">Veronika Müller</searchLink><br /><searchLink fieldCode="AR" term="%22Krisztina+Bogos%22">Krisztina Bogos</searchLink><br /><searchLink fieldCode="AR" term="%22Péter+Nagy%22">Péter Nagy</searchLink><br /><searchLink fieldCode="AR" term="%22István+Kenessey%22">István Kenessey</searchLink><br /><searchLink fieldCode="AR" term="%22András+Wéber%22">András Wéber</searchLink><br /><searchLink fieldCode="AR" term="%22Mihály+Pálosi%22">Mihály Pálosi</searchLink><br /><searchLink fieldCode="AR" term="%22János+Szlávik%22">János Szlávik</searchLink><br /><searchLink fieldCode="AR" term="%22Zsuzsa+Schaff%22">Zsuzsa Schaff</searchLink><br /><searchLink fieldCode="AR" term="%22Zoltán+Szekanecz%22">Zoltán Szekanecz</searchLink><br /><searchLink fieldCode="AR" term="%22Cecília+Müller%22">Cecília Müller</searchLink><br /><searchLink fieldCode="AR" term="%22Miklós+Kásler%22">Miklós Kásler</searchLink><br /><searchLink fieldCode="AR" term="%22Zoltán+Vokó%22">Zoltán Vokó</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Frontiers in Immunology, Vol 13 (2022)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Frontiers Media S.A., 2022.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2022
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Immunologic diseases. Allergy
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22SARS-CoV2+infection%22">SARS-CoV2 infection</searchLink><br /><searchLink fieldCode="DE" term="%22booster+vaccine%22">booster vaccine</searchLink><br /><searchLink fieldCode="DE" term="%224th+vaccine%22">4th vaccine</searchLink><br /><searchLink fieldCode="DE" term="%22omicron+variant+%28SARS-CoV-2%29%22">omicron variant (SARS-CoV-2)</searchLink><br /><searchLink fieldCode="DE" term="%22delta+variant+%28B%2E1%2E617%2E2%29%22">delta variant (B.1.617.2)</searchLink><br /><searchLink fieldCode="DE" term="%22vaccine+effectiveness%22">vaccine effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Immunologic+diseases%2E+Allergy%22">Immunologic diseases. Allergy</searchLink><br /><searchLink fieldCode="DE" term="%22RC581-607%22">RC581-607</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: BackgroundIn Hungary, the pandemic waves in late 2021 and early 2022 were dominated by the Delta and Omicron SARS-CoV-2 variants, respectively. Booster vaccines were offered with one or two doses for the vulnerable population during these periods.Methods and FindingsThe nationwide HUN-VE 2 study examined the effectiveness of primary immunization, single booster, and double booster vaccination in the prevention of Covid-19 related mortality during the Delta and Omicron waves, compared to an unvaccinated control population without prior SARS-CoV-2 infection during the same study periods. The risk of Covid-19 related death was 55% lower during the Omicron vs. Delta wave in the whole study population (n=9,569,648 and n=9,581,927, respectively; rate ratio [RR]: 0.45, 95% confidence interval [CI]: 0.44–0.48). During the Delta wave, the risk of Covid-19 related death was 74% lower in the primary immunized population (RR: 0.26; 95% CI: 0.25–0.28) and 96% lower in the booster immunized population (RR: 0.04; 95% CI: 0.04–0.05), vs. the unvaccinated control group. During the Omicron wave, the risk of Covid-19 related death was 40% lower in the primary immunized population (RR: 0.60; 95% CI: 0.55–0.65) and 82% lower in the booster immunized population (RR: 0.18; 95% CI: 0.16–0.2) vs. the unvaccinated control group. The double booster immunized population had a 93% lower risk of Covid-19 related death compared to those with only one booster dose (RR: 0.07; 95% CI. 0.01–0.46). The benefit of the second booster was slightly more pronounced in older age groups.ConclusionsThe HUN-VE 2 study demonstrated the significantly lower risk of Covid-19 related mortality associated with the Omicron vs. Delta variant and confirmed the benefit of single and double booster vaccination against Covid-19 related death. Furthermore, the results showed the additional benefit of a second booster dose in terms of SARS-CoV-2 infection and Covid-19 related mortality.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 1664-3224
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://www.frontiersin.org/articles/10.3389/fimmu.2022.905585/full; https://doaj.org/toc/1664-3224
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.3389/fimmu.2022.905585
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/70e11602c34c455887a03c15bc33e950" linkWindow="_blank">https://doaj.org/article/70e11602c34c455887a03c15bc33e950</link>
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.70e11602c34c455887a03c15bc33e950
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.70e11602c34c455887a03c15bc33e950
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2022.905585
    Languages:
      – Text: English
    Subjects:
      – SubjectFull: SARS-CoV2 infection
        Type: general
      – SubjectFull: booster vaccine
        Type: general
      – SubjectFull: 4th vaccine
        Type: general
      – SubjectFull: omicron variant (SARS-CoV-2)
        Type: general
      – SubjectFull: delta variant (B.1.617.2)
        Type: general
      – SubjectFull: vaccine effectiveness
        Type: general
      – SubjectFull: Immunologic diseases. Allergy
        Type: general
      – SubjectFull: RC581-607
        Type: general
    Titles:
      – TitleFull: Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zoltán Kiss
      – PersonEntity:
          Name:
            NameFull: István Wittmann
      – PersonEntity:
          Name:
            NameFull: Lőrinc Polivka
      – PersonEntity:
          Name:
            NameFull: György Surján
      – PersonEntity:
          Name:
            NameFull: Orsolya Surján
      – PersonEntity:
          Name:
            NameFull: Zsófia Barcza
      – PersonEntity:
          Name:
            NameFull: Gergő Attila Molnár
      – PersonEntity:
          Name:
            NameFull: Dávid Nagy
      – PersonEntity:
          Name:
            NameFull: Veronika Müller
      – PersonEntity:
          Name:
            NameFull: Krisztina Bogos
      – PersonEntity:
          Name:
            NameFull: Péter Nagy
      – PersonEntity:
          Name:
            NameFull: István Kenessey
      – PersonEntity:
          Name:
            NameFull: András Wéber
      – PersonEntity:
          Name:
            NameFull: Mihály Pálosi
      – PersonEntity:
          Name:
            NameFull: János Szlávik
      – PersonEntity:
          Name:
            NameFull: Zsuzsa Schaff
      – PersonEntity:
          Name:
            NameFull: Zoltán Szekanecz
      – PersonEntity:
          Name:
            NameFull: Cecília Müller
      – PersonEntity:
          Name:
            NameFull: Miklós Kásler
      – PersonEntity:
          Name:
            NameFull: Zoltán Vokó
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 16643224
          Numbering:
            – Type: volume
              Value: 13
          Titles:
            – TitleFull: Frontiers in Immunology
              Type: main
ResultId 1